The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.

Inclusion Criteria:

Retrospective enrolment of Myelodysplastic Syndrome (MDS) participants:

• Aged at least 18 years at initial diagnosis of MDS
• Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 January 2019 and 31 December 2022; and
• Diagnosed with MDS within 100 days from the date of diagnostic bone marrow (BM) aspirate

Inclusion criteria for the prospective enrolment of MDS participants:

• Aged at least 18 years at initial diagnosis of MDS; and
• Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 October 2025 and 30 September 2026; and
• Diagnosed with MDS within 100 days from the date of diagnostic BM aspirate

Exclusion Criteria:

• None

The registry will include adults who were/are newly diagnosed with myelodysplastic syndromes (MDS) in Asia (Singapore, South Korea and Taiwan).